Uridine triacetate - an antidote in the treatment of 5-fluorouracil or capecitabine poisoning

References

• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338.
   PubMed Web of Science ®Google Scholar
• Levy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537–3541.
   PubMed Web of Science ®Google Scholar
• Larsson A, Carlsson G, Gustavsson B, et al. Different intravenous administration techniques for 5-fluorouracil: pharmacokinetics and pharmacodynamic effects. Acta Oncol. 1996;35:207–212.
   PubMed Web of Science ®Google Scholar
• Piedbois P, Rougier P, Buyse M, et al., Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J clin oncol. 1998 January 1;16(1):301–308.
   PubMed Web of Science ®Google Scholar
• Pernot S, Velut G, Rh K, et al. 5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases. Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):255–260.. Epub 2017 Dec 7
   PubMed Web of Science ®Google Scholar
• Graf W, Westlin JE, Pahlman L, et al. Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study. Int J Colorectal Dis. 1994;9:35–39.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008 Jul 20;26(21):3523–3529.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36จC46.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andrจฆ T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229–237.
   PubMed Web of Science ®Google Scholar
• Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005 Jul;5(2):89–100.
   PubMedGoogle Scholar
• Saif MW, Black G, Roy S, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 2007 Jul-Aug;13(4):247–256.
   PubMed Web of Science ®Google Scholar
• Saif MW, Hashmi S, Zelterman D, et al. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139–145.
   PubMed Web of Science ®Google Scholar
• Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014 Apr;34(4):1531–1535.
   PubMed Web of Science ®Google Scholar
• Leyva A, van Groeningen CJ, Kraal I, et al. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-Fluorouracil toxicity. Cancer Res. 1984 December;44(12Part 1):5928–5933.
   PubMedGoogle Scholar
• van Groeningen CJ, Leyva A, Kraal I, et al. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep. 1986 July;70(6):745–750.
   PubMedGoogle Scholar
• Peters GJ, Dijk J, Laurensse E, et al. In vitro biochemical and in vivo biological studies of the uridine’ rescue’ of 5-fluorouracil. Br J Cancer. 1988;57:259–265.
   PubMed Web of Science ®Google Scholar
• van Groeningen CJ, Peters GJ, Leyva A, et al. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst. 1989 Jan;81(2):157–162.
   PubMedGoogle Scholar
• Codacci-Pisanelli G, Van Der Wilt CL, Smid K, et al. High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into RNA in murine tumors. Oncology. 2002;62(4):363–370.
   PubMed Web of Science ®Google Scholar
• Klubes P, Cerna I, Meldon MA. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol. 1982;8(1):17–21.
   PubMed Web of Science ®Google Scholar
• Seiter K, Kemeny N, Martin D, et al. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer. 1993;71(5):1875-1881.
   Google Scholar
• van Groeningen CJ, Peters GJ, Nadal JC, et al. Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst. 1991 March;83(6):437–441.
   PubMedGoogle Scholar
• van Groeningen CJ, Peters GJ, Pinedo HM. Reversal of 5-fluorouracil-induced toxicity by oral administration of Uridine. Ann Oncol. 1993 April;4(1):317–320.
   PubMedGoogle Scholar
• Peters GJ, Lankelma J, Kok RM, et al. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol. 1993;31:269–276.
   PubMed Web of Science ®Google Scholar
• Saif MW. Targeting cancers in the gastrointestinal tract: role of capecitabine. Onco Targets Ther. 2009 Feb;18(2):29–41.
   Google Scholar
• Andreica I, Pfeifer E, Rozov M, et al. Fluorouracil overdose: clinical manifestations and comprehensive management during and after hospitalization. J Hemat Oncol Pharm. 2015;5:43–47.
   Google Scholar
• Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol. 1987;14(Suppl 4):3–11.
   PubMed Web of Science ®Google Scholar
• Tsibiribi P, Descotes J, Lombard-Bohas C, et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer. 2006 Mar 1;93(3):E27–E30.
   PubMedGoogle Scholar
• Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008 Jan;134(1):75–82.
   PubMed Web of Science ®Google Scholar
• Lyros E, Walter S, Keller I, et al. Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. Neurotoxicology. 2014;42:8–11.
   PubMed Web of Science ®Google Scholar
• Wang B, Walsh SJ, Saif MW. Pancytopenia and severe gastrointestinal toxicities associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism. Cureus. 2016 Sep 21;8(9):e798.
   PubMed Web of Science ®Google Scholar
• Saif MW, Wilson RH, Harold N, et al. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs. 2001 Jul;12(6):525–531.
   PubMed Web of Science ®Google Scholar
• Saif MW, Smith M, Maloney A. The first case of severe takotsubo cardiomyopathy associated with 5-Fluorouracil in a patient with abnormalities of both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) genes. Cureus. 2016 Sep 14;8(9):e783.
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009 Mar;8(2):191–202.
   PubMed Web of Science ®Google Scholar
• Choi SM, Lee SH, Yang YS, et al. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001 Jun;16(3):328–334.
   PubMed Web of Science ®Google Scholar
• Saif MW, Ezzeldin H, Vance K, et al. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol. 2007 Sep;60(4):503–507.
   PubMed Web of Science ®Google Scholar
• Saif MW. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):89–92.
   PubMed Web of Science ®Google Scholar
• Hamal R, Byrne M, Hachem H, et al. Association of thymidylate synthase (TYMS) polymorphism with adverse events (AEs) of 5-FU/capecitabine (CAP) in pts with GI cancers. J Clin Oncol. 2018;36. suppl; abstr e14561.
   Web of Science ®Google Scholar
• Ichikawa W, Takahashi T, Suto K, et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res. 2006;12:3928–3934.
   PubMed Web of Science ®Google Scholar
• Mauritz R, Peters JG. Pharmacogenetics of colon cancer and potential implications for 5- Fluorouracil-based chemotherapy. Curr Pharmacogenomics. 2006 March;4(1):57–67.
   Google Scholar
• Saif MW, von Borstel R. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemother Pharmacol. 2006;58:136–142.
   PubMed Web of Science ®Google Scholar
• Bamat MK, Tremmel R, OกฏNeil JD, et al. กฐUridine triacetate: an orally administered life-saving antidote for 5-FU overdose,กฑ. J Clin Oncol; 28(15s):9084. abstract 9084 from 2010 ASCO Annual Meeting.
   Google Scholar
• Kelsen DP, Martin D, O’Neil J, et al. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol. 1997;15(4):1511จC1517.
   PubMed Web of Science ®Google Scholar
• Hildalgo M, Villalona-Calero MA, Eckhardt SG, et al. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.J. Clin Oncol. 2000 Jan;18(1):167–177.
   Web of Science ®Google Scholar
• Doroshow J, McCoy S, Macdonald JS, et al. Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. Invest New Drugs. 2006;24(6):537จC542.
   PubMed Web of Science ®Google Scholar
• cited Jul 12, 2018. https://clinicaltrials.gov/ct2/show/NCT00024427
   Google Scholar
• Martin DS, Stolfi RL, Sawyer RC, et al. High-dose 5-fluorouracil with delayed uridine “rescue” in mice. Cancer Res. 1982;42:3964–3970.
   PubMed Web of Science ®Google Scholar
• Klubes P, Leyland-Jones B. Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue. Pharmacol Ther. 1989;41:289–302.
   PubMed Web of Science ®Google Scholar
• Martin DS, Stolfi RL, Sawyer RC. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol. 1989;24:9–14.
   PubMed Web of Science ®Google Scholar
• McEvilly M, Popelas C, Tremmel B. Use of uridine triacetate for the management of fluorouracil overdose. Am J Health Syst Pharm. 2011 Oct 1;68(19):1806–1809.
   PubMed Web of Science ®Google Scholar
• Bamat M, Tremmel R, Helton J, et al. Clinical experience with uridine triacetate for 5-fluorouracil overexposure: an update [abstract]. Ann Oncol. 2013;24(suppl4):iv71.
   Google Scholar
• Ww M, Mw S, Bf E-R, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017 Jan 1;123(2):345–356.
   PubMed Web of Science ®Google Scholar
• Santos C, Morgan BW, Geller RJ. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. Am J Emerg Med. 2017;35(5):802.e7จC802.e8.
   PubMed Web of Science ®Google Scholar
• Oliver WD, Duffy AP, Hausner PF, Case report of capecitabine toxicity and use of uridine triacetate. J Oncol Pharm Pract. 2017 Jan 1:1078155217730662. Epub ahead of print. DOI:10.1177/1078155217730662.
   Web of Science ®Google Scholar
• Blaschke M, Cameron S, Goeschen C, et al. 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer. Int J Clin Pharmacol Ther. 2013;51:56–58.
   PubMed Web of Science ®Google Scholar
• Saif MW, Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Cancer Chemother Pharmacol. 2016 Jul;78(1):151–156.
   PubMed Web of Science ®Google Scholar
• Zurayk M, Keung YK, Yu D, et al. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. J Oncol Pharm Pract. 2019 Jan;25(1):234-238. doi: 10.1177/1078155217732141.
   Web of Science ®Google Scholar